MIV-210 - a potential drug against hepatitis B and HIV - enters phase II
MIV-210 is a nucleoside analogue (NRTI) with potential in the treatment of HIV and hepatitis B (HBV). Good oral bioavailability (allowing administration as a tablet) and high plasma levels have been shown in phase I studies with MIV-210 in healthy volunteers.
Medivir has now initiated a phase IIa study including patients with multi-resistant HIV. The aim of the study is to establish the clinical efficacy of MIV-210 at a specific dose. In this study MIV-210 will be dosed during 2 weeks and is expected to be evaluated within 6 months.
"We are taking MIV-210 into phase II to test our hypothesis that MIV-210 in a relatively low dose has the capacity to help the growing group of HIV patients where current therapy is not sufficient. With positive results there is a big potential for MIV-210 within the HIV indication. In parallel we see possibilities for MIV-210 against another serious virus infection; hepatitis B" says Johan Harmenberg, VP Clinical Development in Medivir.
In pre-clinical trials MIV-210 has been shown to be an effective inhibitor of multi-resistant HIV strains as well as hepatitis B virus (HBV). In cell culture tests, MIV-210 has retained good activity on HBV which has become resistant against other drugs on the market.
In Medivir's opinion a favourable outcome of the newly initiated study would considerably increase the possibilities in finding a partner to the project prior to the further clinical development.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
